PRINCETON, N.J., April 19 /PRNewswire-FirstCall/ -- Pharmacopeia , an innovator in the discovery and development of novel small molecule therapeutics, announced today that Les Browne, Ph.D., President and Chief Executive Officer, will chair a panel of industry and FDA leaders at BIO2007 in Boston entitled, “Safe or Effective? The FDA’s, the Industry’s and the Patient’s Regulatory Dilemma.”
Panelists: Joshua Boger, Ph.D., Chairman, President & Chief Executive Officer Vertex Pharmaceuticals Inc. Moncef Slaoui, Ph.D., Chairman, Research & Development, GlaxoSmithKline Steven Paul, M.D., Executive Vice President, Science & Technology; President, Lilly Research Laboratories, Eli Lilly & Company Alfred Sandrock, M.D., Ph.D., Senior Vice President, Neurology Research & Development, Biogen Idec, Inc. Scott Gottlieb, M.D., Resident Fellow, American Enterprise Institute A representative from the FDA is also scheduled to participate. Moderator/Chair: Leslie J. Browne, Ph.D., President & Chief Executive Officer Pharmacopeia Panel Description: Safe or Effective? FDA’s, the Industry’s and the Patient’s Regulatory Dilemma Recently highly publicized product withdrawals have significantly heightened public awareness of potential drug side effects. The pressures on the FDA to scrutinize ever more closely a potential new drug’s safety profile has never been greater, which translates into pressure on the industry to invest ever increasing, and increasingly untenable amounts, into clinical studies and to terminate development of potential life-saving or life-enhancing new drugs. The panel will explore this dilemma and address the “hard” questions about the impact on the launch of new drugs brought about by increasing regulatory challenges; the panel will look at the questions from the viewpoint of the FDA, the industry and, importantly, the patient. Date and Time: Wednesday, May 9, 2007, 11:00 AM Location: Boston Convention & Exhibition Center Room 258A Track: Regulatory
ABOUT PHARMACOPEIA
Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia’s most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia’s collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development. Pharmacopeia’s current strategic partnerships are with Cephalon, GlaxoSmithKline, Organon and Wyeth.
Contact: Amy P. Sharpless Pharmacopeia (609) 452-3643 ir_pr@pharmacopeia.com
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia’s strategic plans, Pharmacopeia’s plans to develop PS433540, a compound from its DARA program, Pharmacopeia’s Phase 1 clinical studies and proposed Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia’s ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia’s ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia’s ability to raise additional capital, Pharmacopeia’s expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia’s anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia’s expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia’s ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.
Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia’s Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward- looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.
Pharmacopeia
CONTACT: Amy P. Sharpless of Pharmacopeia, +1-609-452-3643, orir_pr@pharmacopeia.com
Web site: http://www.pharmacopeia.com//
